Study wrapper · #1065
Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.
Editor's note
This population-level utilization study quantifies the sharp rise in semaglutide and tirzepatide use in Australia and highlights that a large share is accessed privately, outside subsidized care. It speaks to real-world demand, supply shortages, and equity of access rather than to efficacy or safety. The findings are descriptive and useful context for readers tracking market and access dynamics.
Plain-language abstract
A national pharmaceutical sales analysis found that use of GLP-1 medicines for type 2 diabetes in Australia rose nearly ten-fold from 2020 to 2025, driven largely by semaglutide and tirzepatide, with almost half accessed through private prescriptions. This is a drug-utilization and access study rather than a clinical outcomes trial.